Vinay Prasad explores three reasons why clinicians should have reservations about the findings from PARADIGM-HF.
This week’s topics include aortic valve stenosis, presenting the benefits of PCI to patients, and more.
CardioExchange’s Harlan M. Krumholz interviews Dr. Jagat Narula about his research group’s study of remote, robot-assisted echocardiographic technology and its applications worldwide.
CardioExchange is dedicated to bringing you the latest from ESC.14. Check out our coverage of the conference here at CardioExchange and don’t forget to tell us what you think! News: PARADIGM-HF Establishes a New Paradigm for Heart Failure Treatment SIGNIFY Trial Provokes Sound and Fury Over Controversial Drug Preliminary Outcomes Results For PCSK9 Inhibitor New Support…
John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.
Larry Husten analyzes the expectations surrounding the upcoming release of PARADIGM-HF and its centerpiece LCZ696 from the perspective of the medical field as well as the world of economics.
A 57-year-old woman with paroxysmal atrial fibrillation, long-QT syndrome after ICD implantation, and severe anxiety presents a unique diagnostic challenge.
In this scenario based on the HPS2-THRIVE study, Harlan Krumholz asks, “What do you say to your patient?”
Harlan Krumholz interviews Sripal Bangalore about his research group’s study of the prognostic value of non-fasting lipid panels.
This week’s topics include the three sodium studies from NEJM, the CLARIFY study, and more.